The Journal of Clinical Investigation (Jun 2022)

PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors

  • Rebekka Duhen,
  • Olivier Fesneau,
  • Kimberly A. Samson,
  • Alexandra K. Frye,
  • Michael Beymer,
  • Venkatesh Rajamanickam,
  • David Ross,
  • Eric Tran,
  • Brady Bernard,
  • Andrew D. Weinberg,
  • Thomas Duhen

Journal volume & issue
Vol. 132, no. 12

Abstract

Read online

CD4+ Th cells play a key role in orchestrating immune responses, but the identity of the CD4+ Th cells involved in the antitumor immune response remains to be defined. We analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4+ Th cells distinct from FOXP3+ Tregs that coexpressed programmed cell death 1 (PD-1) and ICOS. These tumor-infiltrating lymphocyte CD4+ Th cells (CD4+ Th TILs) had a tissue-resident memory phenotype, were present in MHC class II–rich areas, and proliferated in the tumor, suggesting local antigen recognition. The T cell receptor repertoire of the PD-1+ICOS+ CD4+ Th TILs was oligoclonal, with T cell clones expanded in the tumor, but present at low frequencies in the periphery. Finally, these PD-1+ICOS+ CD4+ Th TILs were shown to recognize both tumor-associated antigens and tumor-specific neoantigens. Our findings provide an approach for isolating tumor-reactive CD4+ Th TILs directly ex vivo that will help define their role in the antitumor immune response and potentially improve future adoptive T cell therapy approaches.

Keywords